The anatomical basis for facial itch after epidural morphone is outlined. eNS nuclear events which reactivate latent herpes simplex and immune inhibition resulting in maternal mouth vesicles or neonatal injections are described. Morphine is hypothesized to affect these processes and facial itch is only a marker, not a trigger of this trigeminal opioid activity.
maternal infection at delivery or post partum is primary or recurrent.
A maternal primary infection constitutes the biggest danger to the infant. Neonates are ten times more likely to develop herpes if born to women having a primary rather than reactivated lesion 2 • During reactivation the protective effects of acquired immunity reduce the viral load and shorten the duration of viral shedding. Both herpes simplex 1 (HSV-I) and herpes simplex 2 (HSV-2) have caused neonatal infections. HSV-I accounts for 30-50070 of neonatal herpes. However only 5 to 15% of genital herpes are HSV-I, arousing suspicion of post natal acqusition of HSV-I from siblings, fathers and hospital personneP. In the only Australian reported series', six cases of neonatal herpes occurred in ten years; three were HSV-I and three were HSV-2. None of the mothers gave a history of recent or past herpes infections. Thus, when a mother develops herpes simplex labialis (HSL) post partum, the nearby infants in adjoining cubicles are as much at risk as, if not more than, her own.
Available screening methods miss the majority of patients who give birth to babies infected with herpes simplex. Until newer techniques are developed and tested, current management of pregnant patients is aimed at prevention of herpes infections.
Since 1984, recrudescent, not primary herpes simplex lesions have been reported after the use of epidural and intrathecal opioids 5 "3 (Table 1 ). While epidural morphine is a proven popular safe analgesic after caesarean section, the fact that two unwanted sideeffects, facial itch and HSV-I recrudescence, affect the same fifth cranial nerve, has led to the conclusion that facial itch causes the recrudescence. An alternative view, proposed in this paper, is that itch per se is a marker of opioid activity at both the fifth cranial nerve and "itch centre", but any triggering by morphine of HSV-l reactivation involves trigeminal nuclei or membrane events not dependent on the presence of facial itch. to be an enkephalin mediated, polysynaptic reflex with an afferent spinal arc, whereby excitationlinhibition of dorsal horn cells results in release of endogenous opioids in the caudal nucleus of the trigeminal nerve. Naloxone reversal of facial itch may be due to reversal of exogenous opioid at the site of injection or of endogenous/migrated opioid at the medullary trigeminal nuclei.
THE ANATOMICAL BASIS FOR FACIAL ITCH AFTER OPIOIDS ARE INJECTED INTO THE LUMBAR EPIDURAL SPACE
Opioids, morphine in particular, have a strong ability to induce itch in the territory involving the maxillary division of the trigeminal nerve!4. There are two theories which account for this pruritus which more frequently accompanies intraspinal than parenteral opiate analgesia. Rostral redistribution of opioid molecules from the lumbar site of injection to a remote site in the medulla!5 is consistent with onset times of facial pruritus after lumbar fentanyl, pethidine and morphine. The other is a neuronal effect!6. Acting at a limited spinal segment, opioids may inhibit polysynaptic reflexes, the discharge and transmission of nociceptive information. This perspective considers itch Whether direct receptor or indirect neuronal modulation occurs, the anatomy underlying itch transmission and central nuclei of the trigeminal nerve explains the occurrence of facial itch which results from opiate administration. Itch pain and temperature are transmitted by nerve fibres in the anterolateral quadrant of the spinal cord. Afferent fibres enter the dorsal nerve root by way of the dorsal root ganglion to reach Lissauer's tract. Primary afferents have their cell body in the dorsal root ganglia. The second order neurone has its cell body in the substantia gelatinosa. In the upper cervical region the tract of Lissauer is continuous with the spinal "caudal" nucleus of the trigeminal nerve. A functional similarity has been demonstrated between the spinothalamic and trigeminothalamic tracts l '. In addition, both are rich in opiate receptors l ' (Figure 1 The work of Koenigston l9 and a review by Andreev and Petkov 20 suggest that a "scratch centre", for the relay of itch modality, is located near the floor of the fourth ventricle. It is in the lower part of the medulla oblongata at the level of the obex, bounded cranially by the auditory nuclei and caudally by the inferior cerebellar peduncle oblongata ( Figure 2 ). Neural input from the "scratch" centre and spinal afferent collaterals to trigeminal nuclei account for the sensation of itch rather than facial cold, warmth or paraesthesia after spinal opioids ( Figure 3 ).
Generalized pruritus has been reported with spinal diamorphine, morphine, pethidine, and fentanyl, but not exogenous beta endorphin 2l • Its onset then follows widespread alteration in sensory modulation as the opioid molecule or effect migrates up over the spinal cord. Facial pruritus results from rapid penetration to It is common after spinal opioids, regardless of whether a patient is to suffer an episode of HSL. Facial itch indicates opioid receptor activity, involving central connections of the trigeminal nerve, and is not necessarily a harbinger of HSV-l recrudescence".
Only about 1070 of trigeminal neurones are latently infected in patients prone to HSL. Directly or indirectly, intraspinal opioid may stimulate both infected and healthy trigeminal neurones, when facial itch occurs. On this anatomical basis, it is postulated that opioid trigeminal receptor occupancy and gene effect, not the accompanying itch, may trigger reactivation of HSV-l. Consideration is now given to possible actions whereby morphine may change a trigeminal neurone so that latent HSV-l is reactivated.
MORPHINE AND HSV-l LATENCY
A unique characteristic of the herpes viruses is their ability to establish latent infection, persist in an apparently repressed state for a varying duration and then be reactivated to an infectious replicating form. The reactivation of a latent virus is a well recognized biological phenomenon but not understood from a molecular standpoint. A variety of stimuli have been demonstrated to induce recurrent HSV-l infections, ultraviolet light, fever, stress, menstruation. It occurs in 50-70070 of seropositive patients undergoing trigeminal nerve decompression 23, 10-15070 having dental extractions'" and 3.5-10070 of caesarean section patients given epidural morphine'o",. Until the mechanism of viral latency is elucidated, morphine's role in HSV-l reactivation must remain speculative. The pathogenesis of latency and recrudescence must be understood to see how morphine could modi fy these processes.
There are structural and functional differences between HSV-l in the latent and replicating forms.
The replicating infectious cycles last about 18 hours. Neuronal infection begins with fusion of the virus with heparan sulphated proteoglycans on the plasma cell membrane. The viral envelope is left at the site of entry into the cell. Thus HSV-l specific Fc receptors ± F ab binding sites are expressed at low levels on the surface of neurones immediately after exposure to the virus 25 . Two proteins probably from tegument, shut off most host cell synthesis and initiate transcription of viral genes.
The capsid passes retrograde along axones to the somal nuclear membrane. The viral DNA moves through nuclear pores as a linear duplex molecule (Figure 4 ). Viral macro molecular synthesis then proceeds in a strict temporal sequence with the synthesis of protein in three main categories; immediate, early and late. Each represses the production of the previous phase. Most viral structural proteins and glycoproteins appear about nine hours post-infection. The functions of more than 70 HSV-l gene products remain unexplained. Progeny virions are assembled and depart the nucleus by budding through the inner nuclear membrane acquiring their envelope on the way. The genome passes anterograde along the axone then, by transfection, from intra-epithelial nerve endings to epithelial cells in the trigeminal neurodermatome. This may result in an asymptomatic infection called a recurrence or (more rarely)26, in a clincially apparent lesion called a recrudescence. Another view of latency is that an anti-sense message to immediate early genes is mediated by an IgG antibody binding to both HSV-l antigen and Fc receptors on the infected neuronal surface 28 • The mechanism of this inhibition is undefined. Derepression may occur by factors which weaken IgG antibody binding. It remains controversial whether HSV-l Fc receptor mediates latency. Morphine may dislodge IgG from the Fc receptor by occupancy, receptor shedding or altered shape or a change in ion channel conductance.
In a seropositive individual, only about 1070 of the trigeminal ganglion cells are latently infected 27 • Intraspinal morphine acts on these and normal neurones of the spinal trigeminal nuclei. At the same time as facial itch occurs, it is postulated that morphine induces a conformational change in the HSV-l latency associated transcript, or LAT RNA. The initiation of a cascade of neuronal events including activation of immediate early genes was recently described by Boorsook 29 • Opioids produce short-or long-lasting modulation of neuronal function by acting at specific mu, delta or kappa receptors on (trigeminal) cell membranes. These receptors are coupled to G proteins which may affect membrane ion channel conductance and adenylate cyclase. Subsequent altered cyclic AMPdependent protein kinase in turn may regulate transcription factors and immediate early genes such as C-fos, JunB, JunD, C-Jun. It is postulated that Anaesthesia and Intensive Care. Vol. 23, No. 4, August, 1995 morphine can similarly regulate immediate early herpes genes and/or HSV-l LAT. Immediate early viral genes may then begin to encode, along with a subset which prevent neuronal destruction. The immediate early and late HSV proteins may then appear as viral replication proceeds.
If intraspinal morphine does trigger HSV-l reactivation, the modern theory of viral latency would point more to this action on infected trigeminal immediateearly genes, LAT, RNA and/or FcAb membrane receptors rather than any other side-effects of intraspinal morphine. Note that in viral replication, triggered by other agents, itch may occur but does not predominate. Prodromal symptoms more often include pain, tingling or numbness in the neurodermatome. Pain usually becomes maximal soon after lesions appear and lessens thereafter.
IMMUNE RESPONSE TO HSV-l
Live infectious HSV-l may be reactivated and shed into saliva, but a cold sore or other lesion (recrudescence) does not necessarily accompany it. While reactivated herpes can be liberated intraepithelially, a vesicle will not occur if cell immunity is intact. Asymptomatic live HSV-l oral shedding has been reported in 5-8% of children 30, 2.9% of adults, and 4% of parturients lO • The viral titre is thought to be 100 to 1000 times lower than during a clinically apparent lesion. Such carriers are important reservoirs of infection.
When cell-mediated host immunity is impaired or delayed, reactivated virus is cleared more slowly and an active ulcerative lesion develops.
Though infections are highly cytopathic, any infected epithelial cells are removed rapidly by the T cell immune response. Permanent tissue damage and chronic inflammation are unusual. (An exception is herpetic infection of the eye. Stromal keratitis and uveitis are thought to be auto-immune pathological disorders in which chronic inflammation, dominated by polymorphonuclear leucocytes, and neovascularization persist 31 .) In contrast to cell-mediated immunity, antibody responses, maternal or neonatal, are unlikely to limit herpes infections. Recrudescences occur despite high circulating antibody titres and are no worse in patients with isolated humoral defects. Protective antibodies in conjunction with cell-mediated immunity may control HSV-l spread from epithelial cells to peripheral neural tissue.
The cell-mediated immune response against HSV-l is crucial to our understanding of morphine's role in herpetic cold sores. If impaired, the severity and frequency of symptomatic lesions is increased, despite normal antibody titres. Morphine has been shown to have a naxolone-reversible effect on certain T lymphocytes. Their protective role has been described 32. After exposure to HSV-l, Langerhan cells transport HSV-l antigens to draining lymph nodes where presentation to T cells takes place. Activated T cells then circulate to the skin. Maximal protection usually requires activation of multiple T cell subpopulations ( Figure 6 ). Both class I and class II major histocompatibility complex (MC H) restricted responses are important. Effector cells involved in "containing" virus include cytotoxic T cells the majority of which are class I MHC restricted and T cells responsible for delayed hypersensitivity, the majority of which appear to be class II MHC restricted. The latter may confer protection by antigen-stimulated release of lymphokines, e.g. interferons which may have a direct anti-viral effect or may activate other nonspecific effector cells.
Macrophages exhibit intrinsic resistance to HSV-l replication, ingest and inactivate HSV-l, destroy infected cells, inhibit viral spread to neighbouring cells and produce complement and other mediators enhancing inflammatory responses to HSV-l.
Interferons produced by infected keratinocytes, infiltrating monocytes and lymphocytes inhibit viral protein synthesis in uninfected adjacent cells. In addition they are chemoattractants for circulating mononuclear cells, modulate natural killer NK cells, upgrade expression of MHC class I and II antigens in surrounding cells thus amplifying immune responses to HSV-l.
The role of natural killer NK cells in human HSV-l infections remains uncertain and currently receives little attention. NK cells exhibit extrinsic antiviral resistance by lysing HSV-l infected cells or inhibiting HSV-l replication in infected target cells 3 3. Target cells are lysed without prior antigenic stimulation. NK cells therefore play a primary immune role against HSV-l. In several immune compromised states (genetic or acquired, e.g. Hodgkin's disease and AIDS) NK cells are depressed, as are other specific and nonspecific immune effectors. Neonatal NK cells have impaired cytotoxicity for HSV-l infected target cells 34 • In pregnancy NK cell number and interferon alphaaugmentation of NK cytotoxicity remain unchanged 35 , but they do have an attenuated response against HSV-l infected target cells 36 • In a certain proportion of dermatology patients with severe recurrent herpes simplex labialis, prostaglandin was found to contribute to reduced NK cell cytotoxicity37.
MORPHINE AND IMMUNE RESPONSE TO HSV-l
The most firmly established effect of morphine is its ability to inhibit human lymphocyte function.
Opioid stereospecificity of this phenomenon and reversal by naloxone have been demonstrated in vitro. Morphine inhibits (and metenkephalin enhances) active rosetting of human T lymphocytes 38 • Chronic morphine exposure prevents expression of T cell surface receptors responsible for rosetting. In vivo mouse studies'9 showed that morphine suppressed NK cytotoxic activity and enhanced the growth of implanted tumours. In a study of heroin addicts 40 the percentage of B cells was the same as controls. The percentage of lymphocytes which rosetted was significantly lower than controls. This T cell depression was reversed by naloxone. There are as yet no monoclonal antibody studies demonstrating mu or epsilon receptors on NK cells.
The immune suppressor effects of morphine are reversible by naloxone and mediated within the central nervous system. The effective dose of morphine in cerebral ventricles were 1000 times smaller than that required systemically. Moreover beta endorphin a morphine analogue that does not cross the blood brain barrier, or placenta, had no effect on NK cytotoxity. A novel type of receptor designated epsilon may be involved 4 !.
At caesarean section, the NK cell response attenuated by pregnancy may be further inhibited by epidural or intrathecal morphine. Where cell-mediated immunity is compromised by stressors, progesterone, fever, prostaglandin, the additional immune suppression may be sufficient to tip the balance and impair clearance of reactivated HSV-l. A recrudescence then occurs. Depending on degree of compromised cell immunity, the cold sore after intraspinal morphine may be correspondingly larger, atypical and more severe than the patient's "usual" recrudescence. Wider dissemination may involve viraemia, varicelliform skin lesions with or without visceral involvement. Normalization of immunologic clearance of HSV-I accompanies recovery of cell-mediated immunity.
Either tolerance of NK cells to morphine inhibition, or reversal by naloxone used to treat itch, may be expected to reduce morphine suppression of T cell function and the likelihood of HSV-I recrudescence.
SUMMARY
To recapitulate, recurrent HSV-I infections after epidural or intrathecal morphine are envisaged to occur in two stages. Morphine at the central trigeminal nuclei or ganglion removes host (?antibody) repression of viral regulatory polypeptide synthesis. Virus replication, axonal migration and intraepithelial shedding then proceeds from nerve endings. At the same time, morphine causes a selective quantitative deficiency in cell-mediated immunity to HSV-l. The virus may then proliferate within the epidermis and cause a local lesion before host immune defences can clear it.
Speculation is a long way from proof. The above description is consistent with the current view of HSV-I in the latent and active phase. It offers a possible explanation why epidural morphine may cause a recrudescence, but does not invariably do so. Many immune functions are potentially involved in the control of herpes virus. It is difficult to draw unambiguous conclusions regarding the relative contribution of a single mechanism.
